Toshimasa Tsujinaka

Toshimasa Tsujinaka

Auto-generated profile, based on publicly available information

Toshimasa Tsujinaka

Department of Surgery, Kaizuka City Hospital, Kaizuka, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
KFKazumasa Fujitani
Kazumasa Fujitani
HYHan-Kwang Yang
Han-Kwang Yang
JMJunki Mizusawa
Junki Mizusawa
YKYoung-Woo Kim
Young-Woo Kim
MTMasanori Terashima
Masanori Terashima
RIREGATTA study investigators
REGATTA study investigators

1 September 2013 in The Lancet
Verified
Journal Article
Closed access
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
KYKazuyoshi Yamamoto
Kazuyoshi Yamamoto
JFJunya Fujita
Junya Fujita
SEShunji Endo
Shunji Endo
JKJunji Kawada
Junji Kawada
MMMasaki Mori
Masaki Mori

23 April 2011
Verified
Journal Article
Closed access
HOHisataka Ogawa
Hisataka Ogawa
KFKazumasa Fujitani
Kazumasa Fujitani
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
KIKenji Imanishi
Kenji Imanishi
HSHatsumi Shirakata
Hatsumi Shirakata
SUShigetoshi Utsumi
Shigetoshi Utsumi

1 May 2015 in European Journal of Cancer
Verified
Journal Article
Open access
KNKazuhiro Nishikawa
Kazuhiro Nishikawa
KFKazumasa Fujitani
Kazumasa Fujitani
HIHitoshi Inagaki
Hitoshi Inagaki
YAYusuke Akamaru
Yusuke Akamaru
STShinya Tokunaga
Shinya Tokunaga
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
The optimal second-line regimen for treating advanced gastric cancer (AGC) remains unclear. While irinotecan (CPT-11) plus cisplatin (CDDP) combination therapy and CPT-11 monotherapy have been explored in the second-line setting, the superiority of second-line platinum-based therapies for AGC patients initially treated with S-1 monotherapy has not yet been evaluated; therefore, we aimed to examine the survival benefit of CPT-11/CDDP combination over CPT-11 monotherapy. AGC patients showing progression after S-1 monotherapy for advanced cancer or recurrence within 6 months after completion of S-1 adjuvant therapy were randomly allocated to CPT-11/CDDP (CPT-11, 60 mg/m(2); CDDP, 30 mg/m(2), q2w) or CPT-11 (150 mg/m(2), q2w). Sixty-eight advanced and 95 recurrent cases were evaluated. The median overall survivals were 13.9 (95% confidence interval [CI]: 10.8-17.6) and 12.7 (95% CI: 10.3-17.2) months for CPT-11/CDDP and CPT-11, respectively (hazard ratio: 0.834; 95% CI: 0.596-1.167, P = 0.288). No significant differences were observed in the secondary end-points, including progression-free survival (4.6 [95% CI: 3.4-5.9] versus 4.1 [95% CI: 3.3-4.9]months) and response rate (16.9% [95% CI: 8.8-28.3] versus 15.4% [95% CI: 7.6-26.5]). The incidences of grade 3-4 anaemia (16% versus 4%) and elevated serum lactate dehydrogenase levels (5% versus 0%) were higher for CPT-11/CDDP than for CPT-11. Exploratory subgroup analysis revealed that CPT-11/CDDP was significantly more effective for intestinal-type AGC, compared with CPT-11 (overall survival: 15.8 versus 14.0 months; P = 0.019). No survival benefit was observed upon adding CDDP to CPT-11 after S-1 monotherapy failure.

13 December 2006
Verified
Journal Article
Closed access
TMTomoki Makino
Tomoki Makino
TTToshimasa Tsujinaka
Toshimasa Tsujinaka
HMHideuki Mishima
Hideuki Mishima
MIMasakazu Ikenaga
Masakazu Ikenaga
TSToshiro Sawamura
Toshiro Sawamura
MMMasayuki Mano
Masayuki Mano

1 April 2012
Verified
Journal Article
Closed access
STShigeyuki Tamura
Shigeyuki Tamura
MIMotohiro Imano
Motohiro Imano
HTHiroya Takiuchi
Hiroya Takiuchi
KKKenji Kobayashi
Kenji Kobayashi
HIHaruhiko Imamoto
Haruhiko Imamoto
OGOsaka Gastrointestinal Cancer Chemotherapy Study Group
Osaka Gastrointestinal Cancer Chemotherapy Study Group